Addressing the Disparity: Treating Childhood Cancer in Low and Middle-Income Countries

By HEOR Staff Writer

December 13, 2023

The Stark Reality of Childhood Cancer Treatment in LMICs

Every year, the World Health Organisation (WHO) reports an estimated 400,000 children and adolescents aged 0-19 develop cancer. The most common types are leukaemias, brain cancers, lymphomas, and solid tumours, such as neuroblastoma and Wilms tumours. High-income countries (HICs), which house only 20% of the world’s children with cancer, boast cure rates exceeding 80%. In stark contrast, Childhood Cancer Treatment in LMICs only manage a 30% cure rate.

The Challenges of Healthcare in LMICs

The economies of most LMICs are at an early stage of development, marked by poverty, health-care worker shortages, weak health systems, low education levels, and limited access to modern technology and healthcare facilities. Paediatric oncology, the specialised field dealing with cancers in children and adolescents, demands a high level of expertise and resources. Unfortunately, these are often lacking in LMICs, exacerbating the problem of childhood cancer.

The Essential Components of Effective Childhood Cancer Treatment

Effective treatment of childhood cancer requires a robust system with specialised diagnostic and therapeutic capabilities. Key elements include trained paediatric oncologists, surgeons, pathologists, radiation oncologists, radiologists, pharmacists, and nurses. Reliable supplies of chemotherapeutic agents, supportive care medications, and blood products are crucial. Diagnostic imaging capabilities and basic laboratory services are also vital. However, even with these in place, treatment abandonment remains a significant cause of treatment failure in many LMICs.

The Importance of National Cancer Plans (NCPs) in LMICs

Most LMICs lack policies to ensure good paediatric oncology care and do not have a National Cancer Plan (NCP). An NCP is a public health programme aimed at increasing diagnosis, reducing the number of deaths, and improving the quality of life of cancer patients. It promotes the development of management guidelines, emphasises early referral pathways, lowers morbidity and mortality, and improves the quality of life of cancer patients, regardless of their birthplace.

Education and Training Initiatives in LMICs

Education and public awareness are crucial components in the fight against childhood cancer. For instance, the CHOC Childhood Cancer Foundation has been collaborating with the Department of Health and Traditional Healers Organisations since 2011 to educate health professionals, healthcare workers, and communities about childhood cancer. This initiative aims to bust myths, reduce stigma, and improve early diagnosis and treatment. Furthermore, CHOC has recently trained its employees and volunteers on how to become effective facilitators and advocates in communities. To date, they have trained close to 30,000 trainees in seven of the nine provinces of South Africa, demonstrating a significant stride towards improving childhood cancer outcomes in LMICs.

Reference url

Recent Posts

Innovations in Haematology Cell Therapy at ASH 2025

By HEOR Staff Writer

December 5, 2025

Advancing Haematology Cell Therapy Innovations at ASH 2025 AstraZeneca is significantly advancing haematology cell therapy with its largest-ever presence at the 67th American Society of Hematology (ASH) Annual Meeting and E...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programm...

By João L. Carapinha

December 4, 2025

How will the EU Health Technology Assessment framework evolve in 2026 to improve clinical evaluations for cancer treatments and advanced therapies? The EU Health Technology Assessment (HTA) initiative coordinates standardized reviews of medicines and devices across Member States, thereby boosting...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
What does the latest WHO guideline reveal about GLP-1 obesity therapies, as released in December 2025? This landmark document establishes the first global standards for integrating glucagon-like peptide-1 (GLP-1) receptor agonists and GIP/GLP-1 dual agonists into chronic obesity management, treat...